COVID-19 vaccine pricing: a BBC guide
24 February 2021. Related: COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
Simon Collins, HIV i-Base
Table 1 is compiled from a BBC online article to roughly show the development funding and estimated pricing of COVID-19 vaccines.
Even if these figures are soon out of date, this ball-park guide, includiding for comparisson between manufacturers might still be useful.
Table 1: Comparative vaccine funding and pricing (December 2020)
| Company | Total funding (£ bn) | ~ % govt | $ per dose * | # doses pre-ordered (bn) |
| AstraZeneca | 8.19 | 15% (1.5 bn) | $4-8 | 3.29 |
| Curevac | 1.25 | 65% (800 m) | $12+ | 0.41 |
| J&J | 0.78 | 40% (350 m) | $10+ | 1.27 |
| Moderna | 1.90 | >95% (1.9 bn) | $25 – 35 | 0.78 |
| Novavax | 1.90 | 65% (1.2 bn) | $16+ | 1.38 |
| Pfizer | 2.25 | 15% (350 m) | $18-19 | 1.28 |
| Sanofi/GSK | 0.57 | <5% (30 m) | $10 – 21 | 1.23 |
| Sanofi/Translate | 0.30 | 0 | ||
| SinoVac | 1.62 | 0 | $13 – 30 | 0.26 |
| Sputnik | NA | NA | $10+ | 0.34 |
* Estimates and subject to trade pricing
Source
BBC business news. Covid vaccines: Will drug companies make bumper profits? (18 December 2020).
https://www.bbc.co.uk/news/business-55170756